ValidCare to Present at CBOutlook on Critical Need for Real World Evidence on CBD

ValidCare to Present at CBOutlook on Critical Need for Real World Evidence on CBD

CEO McCarthy will discuss the need for an industry-level approach to consumer data to address the FDA’s pressing questions on the safety and efficacy of cannabis-derived products

Centennial, Colo. – August 13, 2019 – ValidCare, the market intelligence leader for the CBD market, announced that CEO and Founder Patrick McCarthy will present on “Real World Evidence: Critical CBD Consumer Data for Business Strategy and Policy” at the 6th Annual CBOutlook conference, Thursday, August 15 (2:15 p.m.) at the University of Denver.

The U.S. Food and Drug Administration (FDA) is increasingly vocal about the need for credible information about the safety and efficacy of CBD when used by specific populations and for specific purposes. “The CBD industry has an enormous opportunity and obligation to provide data about its products that can help consumers make informed buying and use decisions,” said Patrick McCarthy, CEO and Founder, ValidCare. “FDA has invited the industry to bring forward safety and efficacy data, and is communicating a continued need for this type of data to support their science-based approach to regulations.”

Amy Abernethy, FDA, asks industry for Real World Evidence on CBDIn a recent post from the FDA, Amy Abernethy, M.D., Ph.D., Principal Deputy Commissioner, said “Science forms the basis for decisions at the U.S. Food and Drug Administration (FDA) and is paramount when it comes to making decisions that will impact the health and safety of the American public. We apply this rigorous, science-based approach to matters large and small that come before the Agency — including with respect to products containing cannabis or cannabis-derived compounds, including cannabidiol (CBD). We recognize that there is significant public interest in these products, for therapeutic purposes and otherwise. At the same time, there are many unanswered questions about the science, safety, and quality of many of these products. As we approach these questions, we do so as a science-based regulatory agency committed to our mission of protecting and promoting public health.”1

“I’m looking forward to talking with attendees about how the CBD industry can collaborate to help answer questions posited by both the FDA and consumers, helping ensure an even greater opportunity for CBD products in the future,” said McCarthy.




# # #

About ValidCare

ValidCare, LLC is the market intelligence platform for the cannabis-derived product industry, powered by real-time consumer experiences. Through the ValidCare community, participants including consumers, product suppliers, researchers, and providers, come together to study, educate, measure and document the consumer experience using canna-based products. ValidCare’s proprietary app (CBD+me™) supports ongoing two-way communication, combining self-reported consumer data with advanced machine learning to deliver aggregated insights that help improve product quality, consistency, effectiveness, and the adoption of industry standards.

For more information, visit or call 844-825-4322.